BACKGROUND/AIMS: The gold standard method for measurement of hepatic steatosis is liver histology. Controlled Attenuation Parameter (CAP) can measure hepatic steatosis non-invasively. We aimed to assess the accuracy of CAP for detection of hepatic steatosis. METHODS: A total of 462 patients (May 2012-January 2017)-89 non-alcoholic fatty liver disease, 182 chronic hepatitis B, 88 chronic hepatitis C and 103 patients with other etiologies who underwent simultaneous liver biopsy and CAP estimation using Transient Elastography (TE) were included. Steatosis was graded as S0: steatosis in 0-5% of hepatocytes, S1: 6-33%, S2: 34-66% and S3: 67-100%. Receiver Operating Characteristic (ROC) curves were plotted to evaluate the accuracy of CAP in detecting hepatic steatosis. Predictors of CAP were assessed by multivariate linear regression model. RESULTS: The mean age ± SD was 33.8 ± 11.6 years; 296 (64.1%) were males. On liver histology, steatosis grades S0, S1, S2 and S3 were seen in 331 (71.6%), 74 (16.0%), 39 (8.4%) and 18 (3.9%), respectively. The median CAP (IQR) values for S0, S1, S2, and S3 steatosis were 206 (176-252) dB/m, 295 (257-331) dB/m, 320 (296-356) dB/m, and 349 (306-363) dB/m, respectively. For estimation of ≥S1, ≥S2, and ≥S3 using CAP, AUROC were 0.879, 0.893, and 0.883, respectively. In multivariate analysis, only BMI (OR 1.18; CI, 1.11-1.26, P < 0.001) and grade of hepatic steatosis (grade 1, OR, 3.94; 95% CI, 1.58-9.84, P = 0.003; grade 2, OR 42.04; 95% CI, 4.97-355.31, P = 0.001 and grade 3, OR 35.83; 95% CI 4.31-297.61, P = 0.001) independently predicted CAP. CONCLUSIONS: CAP detects hepatic steatosis with good accuracy in Indian patients with various etiologies.
BACKGROUND/AIMS: The gold standard method for measurement of hepatic steatosis is liver histology. Controlled Attenuation Parameter (CAP) can measure hepatic steatosis non-invasively. We aimed to assess the accuracy of CAP for detection of hepatic steatosis. METHODS: A total of 462 patients (May 2012-January 2017)-89 non-alcoholic fatty liver disease, 182 chronic hepatitis B, 88 chronic hepatitis C and 103 patients with other etiologies who underwent simultaneous liver biopsy and CAP estimation using Transient Elastography (TE) were included. Steatosis was graded as S0: steatosis in 0-5% of hepatocytes, S1: 6-33%, S2: 34-66% and S3: 67-100%. Receiver Operating Characteristic (ROC) curves were plotted to evaluate the accuracy of CAP in detecting hepatic steatosis. Predictors of CAP were assessed by multivariate linear regression model. RESULTS: The mean age ± SD was 33.8 ± 11.6 years; 296 (64.1%) were males. On liver histology, steatosis grades S0, S1, S2 and S3 were seen in 331 (71.6%), 74 (16.0%), 39 (8.4%) and 18 (3.9%), respectively. The median CAP (IQR) values for S0, S1, S2, and S3 steatosis were 206 (176-252) dB/m, 295 (257-331) dB/m, 320 (296-356) dB/m, and 349 (306-363) dB/m, respectively. For estimation of ≥S1, ≥S2, and ≥S3 using CAP, AUROC were 0.879, 0.893, and 0.883, respectively. In multivariate analysis, only BMI (OR 1.18; CI, 1.11-1.26, P < 0.001) and grade of hepatic steatosis (grade 1, OR, 3.94; 95% CI, 1.58-9.84, P = 0.003; grade 2, OR 42.04; 95% CI, 4.97-355.31, P = 0.001 and grade 3, OR 35.83; 95% CI 4.31-297.61, P = 0.001) independently predicted CAP. CONCLUSIONS: CAP detects hepatic steatosis with good accuracy in Indian patients with various etiologies.
Entities:
Keywords:
ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; AUROC, Area Under Receiver Operating Characteristics Curves; BMI, Body Mass Index; CAP, Controlled Attenuation Parameter; CHB, Chronic Hepatitis B; CHC, Chronic Hepatitis C; IQR, Interquartile Range; LSM, Liver Stiffness Measurement; NAFLD; NAFLD, Non-Alcoholic Fatty Liver Disease; SD, Standard Deviation; fibrosis; hepatitis B virus; hepatitis C virus; liver biopsy
Authors: Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith Journal: Hepatology Date: 2009-03 Impact factor: 17.425
Authors: Seung Soo Lee; Seong Ho Park; Hye Jin Kim; So Yeon Kim; Min-Yeong Kim; Dae Yoon Kim; Dong Jin Suh; Kang Mo Kim; Mi Hyun Bae; Joo Yeon Lee; Sung-Gyu Lee; Eun Sil Yu Journal: J Hepatol Date: 2010-02-02 Impact factor: 25.083
Authors: Gioacchino Leandro; Alessandra Mangia; Jason Hui; Paolo Fabris; Laura Rubbia-Brandt; Guido Colloredo; Luigi E Adinolfi; Tarik Asselah; Julie R Jonsson; Antonina Smedile; Norah Terrault; Valerio Pazienza; Maria Teresa Giordani; Emiliano Giostra; Aurelio Sonzogni; Giuseppe Ruggiero; Patrick Marcellin; Elizabeth E Powell; Jacob George; Francesco Negro Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Robert P Myers; Gilles Pomier-Layrargues; Richard Kirsch; Aaron Pollett; Andres Duarte-Rojo; David Wong; Melanie Beaton; Mark Levstik; Pam Crotty; Magdy Elkashab Journal: Hepatology Date: 2011-11-18 Impact factor: 17.425
Authors: E Tsochatzis; G V Papatheodoridis; E K Manesis; G Kafiri; D G Tiniakos; A J Archimandritis Journal: Aliment Pharmacol Ther Date: 2007-10-05 Impact factor: 8.171
Authors: Mohammad S Kuchay; Narendra S Choudhary; Deepak Sharma; Sonal Krishan; Sunil K Mishra; Jasjeet S Wasir; Manish K Singh; Neeraj Saraf; Swapnil Dhampalwar; Randhir Sud Journal: J Clin Exp Hepatol Date: 2021-10-13